Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 310

1.

Vaccinia and other viruses with available vaccines show marked homology with the HIV-1 envelope glycoprotein: the prospect of using existing vaccines to stem the AIDS pandemic.

Carter CJ.

Immunopharmacol Immunotoxicol. 2012 Apr;34(2):222-31. doi: 10.3109/08923973.2011.596542. Epub 2011 Aug 19.

PMID:
21851326
2.

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT.

Nat Med. 2007 Jan;13(1):100-6. Epub 2006 Dec 24.

PMID:
17187074
3.

Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.

Durali D, Morvan J, Letourneur F, Schmitt D, Guegan N, Dalod M, Saragosti S, Sicard D, Levy JP, Gomard E.

J Virol. 1998 May;72(5):3547-53.

4.

Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.

Chen Z, Huang Y, Zhao X, Ba L, Zhang W, Ho DD.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):412-21. doi: 10.1097/QAI.0b013e3181651bb2.

PMID:
18209682
5.

Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus.

Saltarelli M, Querat G, Konings DA, Vigne R, Clements JE.

Virology. 1990 Nov;179(1):347-64.

PMID:
2171210
6.

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljeström P, Wagner R, Esteban M.

Vaccine. 2007 Mar 1;25(11):1969-92. Epub 2006 Dec 6.

PMID:
17224219
7.

Mapping and characterization of visna/maedi virus cytotoxic T-lymphocyte epitopes.

Wu C, Barbezange C, McConnell I, Blacklaws BA.

J Gen Virol. 2008 Oct;89(Pt 10):2586-96. doi: 10.1099/vir.0.2008/002634-0.

PMID:
18796728
8.

Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine.

Böckl K, Wild J, Bredl S, Kindsmüller K, Köstler J, Wagner R.

PLoS One. 2012;7(4):e34723. doi: 10.1371/journal.pone.0034723. Epub 2012 Apr 11.

9.

Maedi-visna virus and its relationship to human immunodeficiency virus.

Thormar H.

AIDS Rev. 2005 Oct-Dec;7(4):233-45. Review.

PMID:
16425963
10.

[Specific immune responses to human immunodeficiency virus type 1 Gag, Tat, Rev and Nef proteins].

Zhai S, Kang WZ, Yu X, Wang SY, Walker BD, Altfeld M, Sun YT.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2005 Mar;21(2):175-9. Chinese.

PMID:
15766402
11.

Evaluation of live feline immunodeficiency virus vaccines with modified antigenic properties.

Broche-Pierre S, Richardson J, Moraillon A, Sonigo P.

J Gen Virol. 2005 Sep;86(Pt 9):2495-506.

PMID:
16099908
12.

DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.

Akahata W, Ido E, Shimada T, Katsuyama K, Yamamoto H, Uesaka H, Ui M, Kuwata T, Takahashi H, Hayami M.

Virology. 2000 Sep 15;275(1):116-24.

13.

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J, Mejías-Pérez E, Jiménez V, Sánchez C, Sorzano CÓ, Oliveros JC, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler KV, Jacobs BL, Pantaleo G, Esteban M.

J Virol. 2015 Jan 15;89(2):970-88. doi: 10.1128/JVI.02469-14. Epub 2014 Oct 29.

14.

Animal models for HIV infection and AIDS: memorandum from a WHO meeting.

[No authors listed]

Bull World Health Organ. 1988;66(5):561-74.

15.

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.

Amara RR, Smith JM, Staprans SI, Montefiori DC, Villinger F, Altman JD, O'Neil SP, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McNicholl JM, McClure HM, Moss B, Robinson HL.

J Virol. 2002 Jun;76(12):6138-46.

16.

The caprine arthritis encephalitis virus tat gene is dispensable for efficient viral replication in vitro and in vivo.

Harmache A, Vitu C, Russo P, Bouyac M, Hieblot C, Peveri P, Vigne R, Suzan M.

J Virol. 1995 Sep;69(9):5445-54.

17.

Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.

Israel ZR, Edmonson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, Van Opstal O, Bruck C, Bex F, et al.

J Virol. 1994 Mar;68(3):1843-53.

19.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
20.

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.

Letvin NL, Huang Y, Chakrabarti BK, Xu L, Seaman MS, Beaudry K, Korioth-Schmitz B, Yu F, Rohne D, Martin KL, Miura A, Kong WP, Yang ZY, Gelman RS, Golubeva OG, Montefiori DC, Mascola JR, Nabel GJ.

J Virol. 2004 Jul;78(14):7490-7.

Supplemental Content

Support Center